<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Responses of patients with <z:hpo ids='HP_0009733'>gliomas</z:hpo> to temozolomide are determined by O(6)-methylguanine-DNA methyltransferase (MGMT) and mismatch repair (MMR) pathways </plain></SENT>
<SENT sid="1" pm="."><plain>This phase II study (NCT00423150) investigated whether MGMT promoter methylation predicts response in patients with advanced aerodigestive tract and <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> and serum samples were screened for MGMT promoter methylation </plain></SENT>
<SENT sid="3" pm="."><plain>In methylation-positive patients, 150 mg/m(2) temozolomide was administered daily on a 7-day-on, 7-day-off schedule for each 28-day cycle </plain></SENT>
<SENT sid="4" pm="."><plain>The primary efficacy endpoint was response rate (RR) </plain></SENT>
<SENT sid="5" pm="."><plain>MMR status was determined by a microsatellite instability assay </plain></SENT>
<SENT sid="6" pm="."><plain>Among 740 patients screened, 86 were positive for MGMT promoter methylation and enrolled </plain></SENT>
<SENT sid="7" pm="."><plain>Nineteen percent of the screened population (137/740) had confirmed tissue and/or serum MGMT promoter methylation, including 25% (57/229) for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, 36% (55/154) for <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e>, 11% (12/113) for <z:e sem="disease" ids="C0278996" disease_type="Neoplastic Process" abbrv="">head and neck cancer</z:e>, and 5% (13/242) for <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small cell lung cancer</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Among patients with valid methylation results in both tissue and serum samples, concordance was 81% (339/419) </plain></SENT>
<SENT sid="9" pm="."><plain>The majority of enrolled patients (69/86; 80%) had microsatellite stable <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Overall RR was 6% (5/86 partial responses); <z:hpo ids='HP_0000001'>all</z:hpo> responders had microsatellite stable <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Temozolomide resulted in low RRs in patients enriched for MGMT methylation </plain></SENT>
<SENT sid="12" pm="."><plain>MGMT methylation status varied considerably in the patient population </plain></SENT>
<SENT sid="13" pm="."><plain>Although serum methylation assay is an option for promoter methylation detection, tissue assay remains the standard for methylation detection </plain></SENT>
<SENT sid="14" pm="."><plain>The low RR of this cohort of patients indicates that MGMT methylation as a biomarker is not applicable to <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> types, and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific factors may override validated biomarkers </plain></SENT>
</text></document>